

Question for written answer E-004571/2025
to the Commission
Rule 144
Giuseppe Antoci (The Left)

Subject: The availability of Teplizumab for type 1 diabetes patients – regional inequalities in access to treatment and technologies

Recently authorised by the European Medicines Agency, Teplizumab is the first kind of immunotherapy to delay the onset of type 1 diabetes. In Italy, the drug is only available in a few major centres. Despite the large number of cases of type 1 diabetes in Sicily and Sardinia, access there is limited. There are also widespread inequalities in respect of sensors, insulin pumps and hybrid systems, which are regulated by EU law¹. The availability and reimbursement arrangements of these vary from region to region. Under Article 168 of the Treaty on the Functioning of the European Union and Regulation (EU) 2021/522, the EU is committed to reducing unequal access to treatment.

In the light of the above:

1. What steps will the Commission take, including by means of the EU4Health programme and cooperation between the Member States, to reduce time to access and mitigate disparities in the availability of Teplizumab, not least in disadvantaged regions?
2. Will it seek to propose dedicated funding for diabetes research in the 2028-2034 multiannual financial framework?
3. With a view to mitigating inequality of access to innovative technologies, how will it help set up databases on type 1 diabetes and plan for the medical devices needed in places like Sicily, where incidence of the disease is high?

Submitted: 17.11.2025

¹ Regulation (EU) 2017/745.